<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TIMOLOL MALEATE</span><br/>(tye'moe-lole)<br/><span class="topboxtradename">Betimol, </span><span class="topboxtradename">Blocadren, </span><span class="topboxtradename">Istalol, </span><span class="topboxtradename">Timoptic, </span><span class="topboxtradename">Timoptic XE<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">beta-adrenergic antagonist (sympatholytic)</span>; <span class="classification">eye preparation</span>; <span class="classification">miotic</span><br/><b>Prototype: </b>Propranolol<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg, 10 mg, 20 mg tablets; 0.25%, 0.5% ophthalmic solution or gel</p>
<h1><a name="action">Actions</a></h1>
<p>Nonselective beta-adrenergic blocking agent similar to propranolol. Demonstrates antihypertensive, antiarrhythmic, and antianginal
         properties, and suppresses plasma renin activity. When applied topically, lowers elevated and normal intraocular pressure
         (IOP) by unknown mechanism but appears to act by reducing formation of aqueous humor and possibly by increasing outflow. In
         contrast to pilocarpine and other miotics, timolol does not constrict pupil and therefore does not cause night blindness,
         and it does not affect accommodation or visual acuity.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Topically, lowers elevated and normal intraocular pressure (IOP). Orally, therapeutically useful for mild hypertension and
         migraine headaches.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Topically (ophthalmic solution) to reduce elevated IOP in chronic, open-angle glaucoma, aphakic glaucoma, secondary glaucoma,
         and ocular hypertension. May be used alone or in conjunction with epinephrine, pilocarpine, or a carbonic anhydrase inhibitor
         such as acetazolamide. Oral preparation is used as monotherapy or in combination with a thiazide diuretic to prevent reinfarction
         after MI and to treat mild hypertension.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Prophylactic management of stable, uncomplicated angina pectoris and migraine headaches.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Bronchospasm; severe COPD; bronchial asthma; heart failure; pregnancy (category C), lactation, abrupt discontinuation, acute
         bronchospasm, AV block, bradycardia, cardiogenic shock, acute pulmonary edema, compromised left ventricular dysfunction, Raynaud's
         disease. Safety in children is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Bronchitis, patients subject to bronchospasm, asthma; sinus bradycardia, greater than first-degree heart block, heart failure;
         hepatic disease; vasospastic angina, peripheral vascular disease; pheochromocytoma; thyrotoxicosis, hyperthyroidism; right
         ventricular failure secondary to pulmonary hypertension, COPD; stroke, cerebrovascular disease; depression; older adults;
         psoriasis; myasthenia gravis; concomitant use with adrenergic augmenting drugs, e.g., MAO inhibitors.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Glaucoma</span><br/><p>See Appendix A-1.</p><br/><span class="indicationtitle">Hypertension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 10 mg b.i.d., may increase to 60 mg/d in 2 divided doses<br/><br/><span class="indicationtitle">Angina</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1545 mg in 3 divided doses<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with fluid of patient's choice; tablet may be crushed.</li>
<li>Make dosage increases for hypertension at weekly intervals.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> CNS:</span> Fatigue, lethargy, weakness, somnolence, anxiety, headache, dizziness, confusion, psychic dissociation, depression. <span class="typehead">CV:</span> Palpitation, bradycardia, hypotension, syncope, AV conduction disturbances, CHF, aggravation of peripheral vascular insufficiency. <span class="typehead">Special Senses:</span> <span class="speceff-common">Eye irritation</span> including conjunctivitis, blepharitis, keratitis, superficial punctate keratopathy. <span class="typehead">GI:</span> Anorexia, dyspepsia, nausea. <span class="typehead">Skin:</span> Rash, urticaria. <span class="typehead">Respiratory:</span> Difficulty in breathing, bronchospasm. <span class="typehead">Body as a Whole:</span> Fever. <span class="typehead">Metabolic:</span> Hypoglycemia, hypokalemia. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">antihypertensive agents</span>, <span class="classification">diuretics</span> potentiate hypotensive effects; <span class="classification">nsaid</span>s may antagonize hypotensive effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 90% absorbed from GI tract; 50% reaches systemic circulation; some systemic absorption from topical application. <span class="typehead">Peak:</span> 12 h PO; 15 h topical. <span class="typehead">Distribution:</span> Distributed into breast milk. <span class="typehead">Metabolism:</span> 80% metabolized in liver to inactive metabolites. <span class="typehead">Elimination:</span> Excreted in urine. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Check pulse before administering timolol, topical or oral. If there are extremes (rate or rhythm), withhold medication and
            call the physician.
         </li>
<li>Assess pulse rate and BP at regular intervals and more aften in patients with severe heart disease.</li>
<li> 							Note: Some patients develop tolerance during long-term therapy. 						</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Be aware that drug may cause slight reduction in resting heart rate. Learn how to assess pulse rate and report significant
            changes. Consult physician for parameters.
         </li>
<li>Do not stop drug abruptly; angina may be exacerbated. Dosage is reduced over a period of 12 wk.</li>
<li>Report difficulty in breathing promptly to physician. Drug withdrawal may be indicated.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>